Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IL-4 & Insulin Resistance in Atopic Dermatitis
NCT05372003Phase 1Completed
- Sponsor
- Mayo Clinic
- Start
- Aug 2022
- Primary completion
- Feb 2024
- Countries
- 1
01
Overview
Phase 1, open-label trial of dupilumab in atopic dermatitis (AD), sponsored by Mayo Clinic. Primary endpoints: Homeostatic Model Assessment for Insulin Resistance and Matsuda Index. Started Aug 2022; status: completed.
02
Drugs
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT05372003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05372003.